Healthcare entity
Every one of those 1 sits in a single category, market-trends. Chemotherapy-induced myelosuppression (CIM) is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window.
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. Chemotherapy-induced myelosuppression (CIM) is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. Source depth averages 2 original sources per story, versus 2.2 across the same-window beat baseline. We currently track 1 Healthcare story that mention Cosela (trilaciclib), all published on July 27, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Cosela (trilaciclib). Shared-story counts are live from our verified record — not editorial picks.
Partnership Announcement
Menarini Asia-Pacific and Pharmacosmos announce exclusive licensing and distribution agreement for Cosela in 11 APAC markets.
Menarini Asia-Pacific partners with Pharmacosmos to bring Cosela, a first-in-class myeloprotective drug, to 11 APAC markets. The deal expands access to supportive oncology care, potentially reducing chemotherapy complications and hospitalizations across the region.
Cosela (trilaciclib) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
